48 results about "Cartilage Matrix" patented technology

The invention belongs to the technical field of microbial fermentation, and particularly relates to lactobacillus rhamnosus capable of maintaining bone health and improving local joint inflammation and a metagen and application of the lactobacillus rhamnosus. According to the invention, the probiotic NKU ML1-2 is subjected to fermentation culture, such that a post-generation product is prepared. Results of embodiments prove that the metagen product can enhance the oxidation resistance of cartilage and osteoblasts and promote the synthesis of anti-inflammatory factors and cartilage matrixes (type II collagen and proteoglycan), and has the potential of relieving oxidative stress and inflammatory response of local joints, relieving joint inflammation and delaying cartilage destruction. The prepared metagen product is high in safety and good in stability, and can be applied to preparation of medicines for preventing and / or treating osteoarthritis; the metagen product can also be used for promoting bone health, enhancing the antioxidant capacity of osteoblasts and / or chondrocytes, promoting osteoblast activity and / or promoting calcium absorption and fixation, and a new solution is provided for joint health management.

The gadolinium-based cationic polymer contrast agent is synthesized by chelating a cationic polymer and gadolinium ions, has high biological safety and can be used for cartilage imaging. The prepared contrast agent adopts an articular cavity direct injection method, so that the imaging effect is improved, and the contrast dosage is reduced. When the cartilage activity is normal, the content of glycosaminoglycan in the matrix is rich, and when the cartilage is inactivated or the activity is reduced, the content of glycosaminoglycan in the matrix is obviously reduced. The gadolinium-based cationic polymer contrast agent is combined with negatively charged glycosaminoglycan in a cartilage matrix through the charge effect. The gadolinium-based cationic polymer contrast agent can be used for noninvasive and quantitative evaluation of cartilage activity in nuclear magnetic resonance imaging, especially cartilage activity and stability in transplantation.

The invention discloses a parasitic loranthus exosome-like nano vesicle and application thereof in preparation of a medicine for treating temporomandibular joint osteoarthritis. The taxillus sutchuenensis exosome-like nano-vesicles are prepared by combining a differential ultracentrifugation method with an ultrafiltration method. Researches show that the taxillus sutchuenensis exosome-like nano-vesicles can treat temporomandibular joint osteoarthritis through the following aspects: 1) an anti-inflammatory function: effectively reducing expression of inflammatory factors; 2) a cartilage degeneration inhibition function: blocking a cartilage matrix degradation pathway, and slowing down cartilage tissue damage; the taxillus sutchuenensis exosome-like nano-vesicles have the advantages that the taxillus sutchuenensis exosome-like nano-vesicles have obvious protection and repair effects on relieving temporal-mandibular joint osteoarthritis related bone and cartilage damage, and accordingly the taxillus sutchuenensis exosome-like nano-vesicles have good application prospects.

A method for modeling temporomandibular joint osteoarthritis, 6-week-old rats are selected, the rats are confirmed to have entered an anesthetized state before surgery, the rat's mandibular incisors are first checked and confirmed to be normal, the first arm of the device is sleeved on one side of the mandibular incisor, and the palatal side of the maxillary incisor is made to touch the slope surface of the second arm of the device, the device is checked and confirmed to not affect the rat's mandibular movement and occlusion, not significantly raise the bite, have no early contact, and the upper and lower jaw relationship is relatively stable; the device and the mandibular incisor sleeved with the device are fixed; then the rat is put back into the cage, and soft food or powdered feed is given after waking up; the device is removed after being fed for 8 weeks or more. It is verified that the condylar process of the rat changes significantly, the overall condylar process is significantly reduced, the subchondral bone is destroyed, and the expression of the cartilage matrix is also reduced. Thus, a TMJOA rat model exhibiting mandibular retrusion is formed.

The invention discloses application of rebaudioside B in preparation of a medicine for preventing and treating metabolism-related osteoarthritis, and belongs to the technical field of biological medicine. Animal experiments prove that the application of the natural micromolecular monomer rebaudioside B in preventing and treating osteoarthritis induced by high fat diet shows that the rebaudioside B can realize a cartilage protection effect by improving lipid deposition, regulating inflammatory response and promoting cartilage matrix synthesis; the method is suitable for intervention and prevention and treatment of metabolism-related osteoarticular diseases. The invention provides a set of intervention scheme with clear structure, multi-target action, clear mechanism and controllable path for the prevention and treatment of metabolism-related osteoarthritis, and provides a scientific basis for the application of rebaudioside B in the prevention and treatment of metabolism-related osteoarthritis.

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and / or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.

The present disclosure relates to a method of treating arthritis by targeting Tankyrase. The methods according to the present disclosure can be advantageously used for regeneration of cartilage tissue and for treating osteoarthritis by maximizing the matrix synthesis in cartilage by inhibition of Tankyrase and regulation of other proteins related therewith.

The application discloses a kind of for repairing cartilage decellularized cartilage matrix support and apoptotic corpuscle composition and its preparation method, composition includes: microporous support, support includes decellularized cartilage outer matrix and crosslinked organic polymer;Apoptotic corpuscle, apoptotic corpuscle exists in microporous support;Wherein, based on the volume 3.14mm 3 Microporous support, 0.01-0.02ug of apoptotic corpuscle is included.The combined support of the application can improve the activity of apoptotic corpuscle, prolong the action time of apoptotic corpuscle, achieve the effect of slow release, also can regulate joint cavity microenvironment, effectively promote joint cartilage repair, improve the repair effect of loss cartilage, avoid the security risks brought by traditional exogenous cell transplantation.

The application relates to an anti-inflammatory and cartilage regeneration promoting material, a preparation method and application thereof, and belongs to the technical field of biomedical materials. The anti-inflammatory and cartilage regeneration promoting material comprises a PLGA (50:50) polymer material, and a huperzine A derivative dimer loaded on the PLGA (50:50) polymer material through 3D printing. The application also provides the use of the anti-inflammatory and cartilage regeneration promoting material in the preparation of anti-inflammatory, cartilage protection or cartilage regeneration promoting drugs. The PLGA / A10E scaffold has good biocompatibility, the PLGA / A10E scaffold degradation release liquid can effectively promote the differentiation of cartilage precursor cells into cartilage, and increase the formation of cartilage collagen matrix and cartilage proteoglycan. The in-vitro degradation liquid of the PLGA / A10E scaffold can promote the expression of SOX9 under non-inflammatory conditions; under LPS-mediated inflammatory conditions, the expression of MMP-13 can be inhibited, thereby promoting the synthesis of cartilage matrix and inhibiting the degradation of cartilage matrix.

A pharmaceutical compositions includes GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. The composition induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and / or stem cell differentiation into chondrocytes.

The invention discloses a mesenchymal stem cell compound preparation for treating cartilage injury, and belongs to the technical field of cell biology. The composite preparation consists of human umbilical cord mesenchymal stem cells (hUC-MSC) subjected to specific pretreatment and a pharmaceutical carrier. The pretreatment method sequentially comprises the following steps: carrying out low-oxygen pretreatment on the hUC-MSC; then, carrying out pretreatment on a ferroptosis inhibitor Ferrostatin-1 under a low-oxygen condition; and finally, carrying out icariin pretreatment under a normal oxygen condition. The unique triple pretreatment strategy generates a remarkable synergistic effect, and can greatly improve the survival rate and the function maintenance capability of the hUC-MSC in the cartilage injury inflammatory microenvironment. Experimental results prove that the preparation can significantly inhibit collagen degradation and promote cartilage matrix regeneration, and the treatment efficiency of stem cell transplantation and the repair effect of cartilage injury are effectively improved.

The invention provides injectable hyaluronic acid hydrogel based on dynamic chemical bonds as well as a preparation method, application and a sol-gel conversion method of the injectable hyaluronic acid hydrogel, and belongs to the technical field of hydrogel. The preparation method comprises the following steps: oxidizing and modifying hyaluronic acid by adopting sodium periodate to obtain formylation modified hyaluronic acid, and carrying out Schiff base reaction on 3, 3 '-dithiodipropionyl hydrazine serving as a cross-linking agent and the formylation modified hyaluronic acid to prepare the injectable hyaluronic acid hydrogel. The HA-SS hydrogel provided by the invention not only has controllable gelation time, but also has excellent deformation resilience, elastic property and good biocompatibility, and can effectively simulate the structure and function of proteoglycan in a cartilage matrix. Due to the existence of the acylhydrazone bond and the disulfide bond, the injectable hyaluronic acid hydrogel based on the dynamic chemical bond has good rapid self-healing and pH / redox dual response performance.

The invention relates to the technical field of gene engineering, particularly discloses application of an NSUN2 gene in preparation of a product for diagnosing or treating osteoarthritis, and has the technical key points that the invention reveals that the NSUN2 has a potential value of serving as a clinical diagnosis biomarker; meanwhile, by knockdown and overexpression of the NSUN2 and detection of senescence and cartilage matrix synthesis and catabolism related indexes in cartilage cells, the invention finds that the NSUN2 can inhibit synthesis and secretion of cartilage matrix and promote cartilage senescence, and the increase of the NSUN2 is an important factor causing osteoarthritis, which indicates that the NSUN2 is expected to be used as a target to treat osteoarthritis.

The invention provides a tribenzoyl substituted vakognavine type diterpenoid alkaloid, a preparation method and application of the tribenzoyl substituted vakognavine type diterpenoid alkaloid, and a pharmaceutical composition. After rats are treated by the tribenzoyl substituted vakognavine type diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

This invention provides a stress-triggered selective targeting hydrogel microsphere, its preparation method, and its application, belonging to the field of biomedical technology. The core of this invention is the "stress-triggered charge reversal" mechanism. It utilizes the interaction between weakly cross-linked disulfide bonds broken under stress and "charge reversal" messenger molecules to achieve "charge reversal" of nanoparticles under stress. A dual-network hydrogel microsphere system is prepared using microfluidic technology to achieve bearing lubrication and stress relaxation within the joint cavity. Stress-triggered charge reversal is achieved at stress-overloaded cartilage lesions, imparting a positive charge to the drug-loaded nanoparticles within the hydrogel microspheres. This significantly enhances the ability of the drug-loaded nanoparticles to penetrate deep into the cartilage matrix and target chondrocytes for drug release under the guidance of the charge. This enables the selective and targeted release of appropriate drug concentrations to deep-seated chondrocytes in pathological microenvironments induced by different stress intensities, achieving highly effective and low-toxicity treatment of osteoarthritis.

The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of an amniotic fluid active complex. According to the method, inherent physical and chemical differences of different components in amniotic fluid are utilized, through a series of physical steps, the components are firstly and mildly grouped and enriched according to categories, and then the components are guided to be self-assembled again under controllable conditions to form a composite particle with a compact structure. The natural aggregation state of active ingredients in a living body before secretion or action is simulated, so that the multi-element active ingredients which naturally coexist and interact in amniotic fluid are efficiently captured and transferred as a complete functional unit, the natural ingredient spectrum is not damaged, and the original advanced structure and function are not lost. The invention provides application of an amniotic fluid active complex (RSC) in treating or preventing joint diseases or symptoms. The RSC has obvious effects in promoting cartilage matrix synthesis, inhibiting moderate and mild osteoarthritis and relieving pain.

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.

The invention provides Haitesan type diterpenoid alkaloid as well as a preparation method, application and a pharmaceutical composition thereof. After rats are treated by the Haitesan diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

The invention provides diterpenoid alkaloid in delphinium delphinium as well as a preparation method, application and a pharmaceutical composition of the diterpenoid alkaloid. After rats are treated by diterpenoid alkaloid in delphinium delphinium provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

The invention provides a composition for improving bone joints and promoting bone health as well as a preparation method and application thereof, and relates to the technical field of compositions. The composition is prepared from N-acetylglucosamine and a turmeric extract. The composition can improve the differentiation activity of cartilage precursor cells, effectively promote synthesis of cartilage matrixes, increase the structural construction ability of cartilage tissues, reverse expression down-regulation of cartilage synthesis markers, down-regulate abnormally high expression of cartilage decomposition markers and maintain metabolic balance of cartilage synthesis and decomposition, and has the effects of improving the cartilage tissue differentiation activity and improving the cartilage tissue differentiation activity. Abnormal high secretion of tumor necrosis factors alpha and interleukin 6 in LPS-induced cartilage cells is reduced, and the effects of resisting inflammation, resisting cartilage degradation and maintaining cartilage metabolism balance are achieved.

The invention provides C20 type diterpenoid alkaloid, a preparation method and application thereof and a pharmaceutical composition. After rats are treated by the C20 type diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

This specification discloses an oligonucleotide capable of specifically hybridizing with miR-204, and compositions comprising the oligonucleotide for improving, preventing, or treating osteoarthritis. In one aspect, the oligonucleotide is designed with an optimized structure for miR-204 degradation and formulation stability, effectively blocking pathophysiological processes of osteoarthritis such as decreased cartilage matrix synthesis and increased inflammatory response, thereby preventing or treating osteoarthritis. Furthermore, it exhibits excellent delivery capability to chondrocytes and stable residence within tissues, thus possessing structural advantages for achieving long-term, sustained therapeutic effects. It also has low immunogenicity and toxicity, possessing safety suitable for use in pharmaceutical compositions. In addition, it effectively inhibits miR-204 in canine chondrocytes, therefore it can be used in animal therapeutics and / or feed compositions, etc.

The invention belongs to the technical field of biotechnology and tissue engineering, and particularly relates to application of pilose antler bone matrix vesicles in preparation of a medicine for treating bone injury, in the pilose antler bone matrix vesicles prepared through an enzymolysis method, the pilose antler cartilage matrix vesicles can remarkably promote cartilage differentiation, the osteogenesis promoting capacity of the pilose antler osteogenesis matrix vesicles is extremely high, and the pilose antler cartilage matrix vesicles can be used for preparing medicines for treating bone injury. The pilose antler bone matrix vesicle can improve bone mineral density, bone volume fraction, bone trabecula number, bone trabecula thickness, bone trabecula separation degree and cortical bone mineral density, can play a significant role in the aspect of osteoporosis resistance, and has good application in the aspect of bone injury treatment.

This invention provides the application of ultrasound-responsive manganese nitrogen coordination-platinum modified mesoporous nitrogen-doped carbon nanozymes in the treatment of suppurative arthritis. This material uses mesoporous nitrogen-doped carbon as a framework, possessing both Mn–N4 multi-enzyme-like active centers and highly dispersed Pt electronic regulatory sites, enabling ultrasound-controlled bidirectional dynamic regulation of ROS. The material is prepared using a coordination-assisted polymerization-template pyrolysis combined with solvothermal post-modification process. During the ultrasound-on phase, it generates ROS to kill drug-resistant bacteria such as MRSA and disrupt bacterial biofilms; during the ultrasound-off phase, it removes excess ROS, decomposes hydrogen peroxide, and improves the joint hypoxia and inflammatory microenvironment. This nanozyme can be formulated for local delivery via intra-articular injection or hydrogel, effectively downregulating inflammatory and cartilage-degrading factors, protecting the cartilage matrix, and repairing bone tissue damage, thus providing highly effective treatment for drug-resistant bacterial-mediated suppurative osteoarthritis.

The invention provides tetrabenzoyl substituted vakognavine type diterpenoid alkaloid as well as a preparation method, application and a pharmaceutical composition of the tetrabenzoyl substituted vakognavine type diterpenoid alkaloid. After rats are treated by the tetrabenzoyl substituted vakognavine type diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

The invention discloses an external-use compound formula for assisting skeletal development and cartilage health of teenagers, and belongs to the technical field of external-use health-care preparations. According to the formula, yak bone marrow peptide, glucosamine hydrochloride, chondroitin sulfate and bone collagen peptide serve as core active ingredients, rose hip oil is matched to serve as a transdermal penetration enhancing component, transdermal absorption of the active ingredients is achieved through reasonable matching, osteoblast metabolism of teenagers (6-18 years old) can be promoted in a targeted mode, the bone mineral density can be increased, and the effect of preventing and treating osteoporosis is achieved. Meanwhile, cartilage matrix synthesis is strengthened, cartilage injury is reduced, and the problem that external health care products are deficient in the teenager skeletal cartilage development stage is solved. According to the technical verification of the Zhejiang traditional Chinese medicine university medicine college modern medicine research center, the formula is high in safety and excellent in transdermal efficiency, adapts to teenager skin barrier characteristics, and has remarkable application value in the fields of teenager skeletal development and cartilage health maintenance.

The invention relates to liquid modified milk and a preparation method thereof, the liquid modified milk comprises animal milk, glucosamine hydrochloride, calcium beta-hydroxy-beta-methylbutyrate and cordyceps militaris extract, the cordyceps militaris extract contains cordycepin and adenosine, the cordycepin content in the liquid modified milk is greater than or equal to 1.6 mg / 100mL, and the adenosine content in the liquid modified milk is greater than or equal to 0.6 mg / 100mL. According to the modified milk provided by the invention, cordycepin enhances the biosynthesis and energy supply capability of mitochondria by activating related signal channels, and provides an energy basis for the GaHMB to play a role, so that the synthesis efficiency of muscle protein is improved; adenosine and glucosamine have a synergistic effect, so that conduction of inflammation-related signals can be blocked, and decomposition of cartilage matrixes is reduced; meanwhile, glucosamine is used as a glycosaminoglycan precursor, under the action of a signal channel regulated and controlled by adenosine, the synthesis efficiency of cartilage tissue can be remarkably stimulated, the utilization efficiency of sugar is improved, and finally triple synergistic intervention of muscle-joint-metabolism is achieved.

The invention discloses nanoparticles and an electromagnetic transfection system for repairing cartilage injury as well as a preparation method and application of the nanoparticles and the electromagnetic transfection system, and belongs to the technical field of biological medicines. The preparation method of the nanoparticles comprises the following steps: S1, carrying out amination modification on SPIONs coated with silicon dioxide, so as to obtain aminated SPIONs; and S2, covalently binding small interfering RNA to the surface of the aminated SPIONs obtained in the S1 through a cross-linking agent, thereby obtaining the product. The si-SIRT3 (at) SPIONs nano delivery system is successfully constructed, non-invasive EMF exposure is combined, the problem that the cartilage tissue transfection efficiency is low is solved, SIRT3 overexpression, primary cilia injury and cartilage matrix degradation caused by factors such as T-2 toxin can be effectively reversed, the obvious cartilage protection and repair effects are shown in vitro and in vivo, and the cartilage tissue transfection system has the advantages of being high in biocompatibility, good in biocompatibility and good in biocompatibility. A novel targeted therapy normal form is provided for treating cartilage injury diseases such as Kaschin-Beck disease.

The invention discloses ROS (reactive oxygen species) response type liposome hydrogel as well as a preparation method and application thereof, and the preparation method comprises the following steps: sequentially preparing drug-loaded liposome, phenylboronic acid modified hyaluronic acid and ROS response type hydrogel, and mixing the drug-loaded liposome and the ROS response type hydrogel to obtain the ROS response type liposome hydrogel. According to the preparation method disclosed by the invention, through surface modification of the cartilage affinity peptide and ROS responsive hydrogel encapsulation, the targeting capability and the retention capability of the medicines resveratrol and chondroitin sulfate are successfully improved, and the purpose of responsive release of the medicines is achieved. According to the ROS response type liposome hydrogel, accumulation of ROS in cells can be reduced, and the inflammatory mediator and matrix degrading enzyme level can be lowered; meanwhile, cartilage matrix degradation and subchondral bone change can be inhibited, development of osteoarthritis is delayed, and the novel delivery system for osteoarthritis treatment has huge potential.

An object of the present invention is to provide a novel drug for suppressing progression of osteoarthritis, particularly, a novel drug for suppressing degeneration and / or loss of cartilage.SOLUTION: The present inventors have clarified that when dabigatran etexilate methanesulfonate, which is a thrombin inhibitor having an effect of inhibiting the production of fibrin from fibrinogen, is administered to a patient with knee osteoarthritis, the value indicating the total amount of cartilage matrix degradation products is decreased. That is, the present invention provides an inhibitor of cartilage degeneration in an osteoarthritic joint, the inhibitor containing a fibrin formation inhibitor as an active ingredient, and means for solving the problem.SELECTED DRAWING: None